Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
University of Michigan Medical School
Ann Arbor, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of Michigan Medical School (26)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism
Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246
-
Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)
Scientific Reports
-
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma
Nature Communications, Vol. 15, Núm. 1
-
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525
2023
-
Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation
Blood, Vol. 141, Núm. 9, pp. 1047-1059
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Regulation and role of the PP2A-B56 holoenzyme family in cancer
Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1878, Núm. 5
-
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8
2022
-
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)
Nature Medicine
-
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential
British Journal of Cancer, Vol. 126, Núm. 11, pp. 1595-1603
-
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Nature Medicine, Vol. 28, Núm. 3, pp. 557-567
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Hematopoiesis under telomere attrition at the single-cell resolution
Nature Communications, Vol. 12, Núm. 1
2017
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502
2016
-
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis
Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477
2015
-
Characterization of large structural genetic mosaicism in human autosomes
American Journal of Human Genetics, Vol. 96, Núm. 3, pp. 487-497
-
Consensus nomenclature for CD8+ T cell phenotypes in cancer
OncoImmunology, Vol. 4, Núm. 4
2014
-
Consensus guidelines for the detection of immunogenic cell death
OncoImmunology, Vol. 3, Núm. 9
-
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma
Cancer Cell, Vol. 25, Núm. 6, pp. 735-747